Lysosomal Storage Diseases Market Segmented By Gaucher's Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis Indication Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy Therapies
Industry: Healthcare
Published Date: October-2016
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 167
Report ID: PMRREP3145
1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Lysosomal Storage Diseases Therapeutics Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.3. Restraints
4.4. Opportunity
4.5.Forecast Factors – Relevance and Impact
4.6. Reimbursement Scenario in U.S.
4.7. Pipeline Analysis
5. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Therapy
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Therapy Type
5.3. Y-o-Y Growth Projections By Therapy Type
5.4. Market Value Forecast By Therapy , 2015–2026
5.4.1. Enzyme Replacement Therapy
5.4.2. Stem-cell Therapy
5.4.3. Substrate Reduction Therapy
5.4.4. Others
5.5. Market Attractiveness By Therapy
6. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Indication
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Treatment Type
6.3. Y-o-Y Growth Projections By Treatment Type
6.4. Market Value Forecast By Indication , 2015–2026
6.4.1. Gaucher's Disease
6.4.2. Fabry Disease
6.4.3. Pompe’s Syndrome
6.4.4. Mucopolysaccharidosis
6.4.5. Others
6.5. Market Attractiveness By Indication
7. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By End User
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis By Treatment Type
7.3. Y-o-Y Growth Projections By Treatment Type
7.4. Market Value Forecast By End User , 2017–2027
7.4.1. Hospitals
7.4.2. Clinics
7.5. Market Attractiveness By End User
8. Global Lysosomal Storage Diseases Therapeutics Market Analysis and Forecasts, By Region
8.1. Basis Point Share (BPS) Analysis By Country
8.2. Y-o-Y Growth Projections By Country
8.3. Market Value Forecast By Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia-Pacific (APAC)
8.3.5. Middle East & Africa (MEA)
8.4. Market Attractiveness By Country/Region
9. North America Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2. Market Value Forecast By Country , 2015–2026
9.2.1. US
9.2.2. Canada
9.3. Market Value Analysis and Forecast By Country & End User, 2015–2026
9.4. Market Value Forecast By Type of Therapy , 2015–2026
9.4.1. Enzyme Replacement Therapy
9.4.2. Stem Cell Therapy
9.4.3. Substrate Reduction Therapy
9.4.4. Others
9.5. Market Value Forecast By Indication , 2015–2026
9.5.1. Gaucher's Disease
9.5.2. Fabry Disease
9.5.3. Pompe’s Syndrome
9.5.4. Mucopolysaccharidosis
9.5.5. Others
9.6. Market Attractiveness Analysis
9.6.4. By Country
9.6.1. By Type of Therapy
9.6.3. By Indication
9.6.2. By End User
9.7. Key Regulations
9.8. Prominent Trends
9.9. Drivers and Restraints: Impact Analysis
10. Latin America (LATAM) Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.2. Market Value Forecast By Country , 2015–2026
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Argentina
10.2.4. Rest of LATAM
10.3. Market Value Analysis and Forecast By Country & End User, 2015–2026
10.4. Market Value Forecast By Type of Therapy , 2015–2026
10.4.1. Enzyme Replacement Therapy
10.4.2. Stem Cell Therapy
10.4.3. Substrate Reduction Therapy
10.4.4. Others
10.5. Market Value Forecast By Indication , 2015–2026
10.5.1. Gaucher's Disease
10.5.2. Fabry Disease
10.5.3. Pompe’s Syndrome
10.5.4. Mucopolysaccharidosis
10.5.5. Others
10.6. Market Attractiveness Analysis
10.6.4. By Country
10.6.1. By Type of Therapy
10.6.3. By Indication
10.6.2. By End User
10.7. Key Regulations
10.8. Prominent Trends
10.9. Drivers and Restraints: Impact Analysis
11. Europe Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.2. Market Value Forecast By Country , 2015–2026
11.2.1. U.K.
11.2.2. France
11.2.3. Italy
11.2.4. Spain
11.2.5. Russia
11.3. Market Value Forecast By Country& End User, 2015–2026
11.4. Market Value Forecast By Type of Therapy , 2015–2026
11.4.1. Enzyme Replacement Therapy
11.4.2. Stem Cell Therapy
11.4.3. Substrate Reduction Therapy
11.4.4. Others
11.5. Market Value Forecast By Indication , 2015–2026
11.5.1. Gaucher's Disease
11.5.2. Fabry Disease
11.5.3. Pompe’s Syndrome
11.5.4. Mucopolysaccharidosis
11.5.5. Others
11.6. Market Attractiveness Analysis
11.6.4. By Country
11.6.1. By Type of Therapy
11.6.3. By Indication
11.6.2. By End User
11.7. Key Regulations
11.8. Prominent Trends
11.9. Drivers and Restraints: Impact Analysis
12. Asia-Pacific (APAC) Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.2. Market Value Forecast By Country , 2015–2026
12.2.1. China
12.2.2. Japan
12.2.3. India
12.2.4. Australia & New Zealand
12.2.5. Rest of APAC
12.3. Market Value Forecast By Country & End User, 2015–2026
12.4. Market Value Forecast By Type of Therapy, 2015–2026
12.4.1. Enzyme Replacement Therapy
12.4.2. Stem Cell Therapy
12.4.3. Substrate Reduction Therapy
12.4.4. Others
12.5. Market Value Forecast By Indication , 2015–2026
12.5.1. Gaucher's Disease
12.5.2. Fabry Disease
12.5.3. Pompe’s Syndrome
12.5.4. Mucopolysaccharidosis
12.5.5. Others
12.6. Market Attractiveness Analysis
12.6.1. By Country
12.6.2. By Type of Therapy
12.6.3. By Indication
12.6.4. By End User
12.7. Key Regulations
12.8. Prominent Trends
12.9. Drivers and Restraints: Impact Analysis
13. Asia-Pacific (APAC) Lysosomal Storage Diseases Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.2. Market Value Forecast By Country , 2015–2026
13.2.1. GCC
13.2.2. South Africa
13.2.3. Rest of MEA
13.3. Market Value Forecast By Country& End User, 2015–2026
13.4. Market Value Forecast By Type of Therapy , 2015–2026
13.4.1. Enzyme Replacement Therapy
13.4.2. Stem Cell Therapy
13.4.3. Substrate Reduction Therapy
13.4.4. Others
13.5. Market Value Forecast By Indication , 2015–2026
13.5.1. Gaucher's Disease
13.5.2. Fabry Disease
13.5.3. Pompe’s Syndrome
13.5.4. Mucopolysaccharidosis
13.5.5. Others
13.6. Market Attractiveness Analysis
13.6.1. By Country
13.6.2. By Type of Therapy
13.6.3. By Indication
13.6.4. By End User
13.7. Key Regulations
13.8. Prominent Trends
13.9. Drivers and Restraints: Impact Analysis
14. Competition Landscape
14.1. Competition Dashboard
14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
14.2.1. Shire PLC
14.2.2. Pfizer, Inc.
14.2.3. Sanofi
14.2.4. BioMarin Pharmaceutical Inc.
14.2.5. Actelion Ltd.
14.2.6. Raptor Pharmaceutical Corp.
14.2.7. Protalix Biotherapeutics Inc.
14.2.8. Amicus Therapeutics, Inc.
15. Assumptions and Acronyms Used
16. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
List of Tables
Table 01: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 02: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 03: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 04: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Region, 2015–2026
Table 05: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 06: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 07: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 08: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 09: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 10: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 11: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 12: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 13: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 14: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 15: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 16: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 17: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 18: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
©2016 Persistence Market Research, All Rights Reserved 19
Table 19: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 20: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Table 21: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Country, 2015–2026
Table 22: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Type of Therapy, 2015–2026
Table 23: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By Indication, 2015–2026
Table 24: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Analysis and Forecast By End User, 2015–2026
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
List of Figures
Figure 01: Global Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2015–2026
Figure 02: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 03: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Type of Therapy, 2016 & 2026
Figure 04: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Type of Therapy, 2016–2026
Figure 05: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Enzyme Replacement Therapy Segment, 2016–2026
Figure 06: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Stem Cell Therapy Segment, 2016–2026
Figure 07: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Substrate reduction Therapy Segment, 2016–2026
Figure 08: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ opportunity By Others Segment, 2016–2026
Figure 09: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 10: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Indication, 2016 & 2026
Figure 11: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Indication, 2016–2026
Figure 12: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Gaucher's Disease Indication Segment, 2016–2026
Figure 13: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Fabry Disease Indication Segment, 2016–2026
Figure 14: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Pompe’s Syndrome Indication Segment, 2016–2026
Figure 15: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Mucopolysaccharidosis Indication Segment, 2016–2026
Figure 16: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Others Indication Segment, 2016–2026
Figure 17: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 18: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By End User, 2016 & 2026
Figure 19: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By End User, 2016–2026
Figure 20: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Hospitals End User Segment, 2016–2026
Figure 21: Global Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity By Clinics End User Segment, 2016–2026
Figure 22: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 23: Global Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Region, 2016 & 2026
Figure 24: Global Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Region, 2016–2026
Figure 25: North America Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 26: Latin America Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 27: Europe Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 28: Asia Pacific Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 29: MEA Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 30: Global Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Region, 2016–2026
Figure 31: North America Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 32: North America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 33: North America Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 34: The U.S. Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 35: Canada Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 36: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 37: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 38: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 39: North America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 40: Latin America Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 41: Latin America Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 42: Latin America Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 43: Brazil Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 44: Mexico Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 45: Argentina Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 46: Rest of Latin America Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 47: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 48: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 49: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 50: Latin America Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 51: Europe Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 52: Europe Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 53: Europe Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 54: Germany Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 55: France Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 56: U.K. Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 57: Spain Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 58: Italy Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 59: Russia Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 60: Rest of Europe Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 61: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 62: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 63: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 64: Europe Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 65: APAC Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 66: APAC Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 67: APAC Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 68: China Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 69: Japan Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 70: India Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 71: Australia & New Zealand Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 72: Rest of APAC Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 73: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 74: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 75: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 76: APAC Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
Figure 77: MEA Lysosomal Storage Diseases Therapeutics Market Share Analysis (%) By Country, 2016 & 2026
Figure 78: MEA Lysosomal Storage Diseases Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 79: MEA Lysosomal Storage Diseases Therapeutics Y-o-Y growth (%) By Country, 2016–2026
Figure 80: GCC Countries Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 81: South Africa Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 82: Rest of MEA Lysosomal Storage Diseases Therapeutics Market Absolute $ Opportunity, 2016–2026
Figure 83: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Country, 2016–2026
Figure 84: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Type of Therapy, 2016–2026
Figure 85: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By Indication, 2016–2026
Figure 86: MEA Lysosomal Storage Diseases Therapeutics Market Attractiveness Analysis By End User, 2016–2026
